Time is prognosis: Early treatment of HF in both acute and chronic settings
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
16 September 2024
Valid for credit through:
15 September 2025
CME accredited by:
16 September 2024 - 15 November 2024
Hong Kong College of Community Medicine - 1.0
Hong Kong College of Emergency Medicine - 1.0
The Hong Kong College of Pathologists - 1.0
Hong Kong College of Physicians - 1.0
CME accredited by:
16 September 2024 - 15 September 2025
Hong Kong Doctors Union - 1.0
Endorsed by:
Hong Kong Doctors Union
CRMSynced Forum is a professional, integrated educational platform for Hong Kong healthcare professionals to receive the latest updates on international guidelines for cardio-renal-metabolic disease and related information, such as case reports, insightful articles and lectures. The platform includes interviews with numerous key opinion leaders (KOLs) in the field, from whom local healthcare professionals can gain valuable insights.
About the programme
Heart failure is often underrecognized despite early warning signs. Delays in diagnosis and appropriate treatment can significantly worsen prognosis. By the time a patient is hospitalized for HF, the risk of rehospitalization and mortality has greatly increased. In this webinar, Professor Javed Butler from the University of Mississippi, United States, discussed data on the use of empagliflozin in HF patients, highlighting the benefits of early initiation in both chronic and acute settings as reflected by the latest guidelines. He also emphasized that medications such as sodium-glucose cotransporter 2 inhibitors exert a comprehensive impact across diverse cardio-renal-metabolic (CRM) conditions due to their direct and indirect actions, which collectively offer risk reduction across these interconnected disease states.
Professor Javed Butler
Distinguished Professor of Medicine,
University of Mississippi,
United States
This is an independent editorial article, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher, and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.